TransCelerate has added Pharmacovigilance to its portfolio, establishing two new global initiatives: 1.) Interpretation of Pharmacovigilance Regulations and 2.) Value of Safety Information Data Sources. Both initiatives aim to create solutions that will reduce resource inefficiencies, enhance information exchange with global health authorities and improve patient safety to drive more value for patients.
Read this release about TransCelerate BioPharma Inc.’s measurable progress in its mission to help drive the efficient, effective and high-quality delivery of new medicines for patients through the sharing of data, and harmonizing on critical challenges in clinical trials.
Read this piece featuring our leader, Ed Bowen of Pfizer who highlights the implications of high placebo response in the drug development process.
Read this interview with TransCelerate’s QMS leader, Deb Driscoll discussing how the initiative aims to bring together industry stakeholders to explore ways to improve quality in clinical trials, and this initiative’s progress.
TransCelerate BioPharma introduced two new solutions through its Site Qualification and Training Initiative, both supporting the mission of simplifying and accelerating the R&D of new therapies.
TransCelerate announced the availability of 11 optimized informational programs through its Site Qualification and Training Initiative.
Read this perspectives piece from Brett Wilson, head of Monitoring Excellence at Bristol-Myers Squibb (BMS), and leader of the TransCelerate RBM Initiative.
TransCelerate BioPharma addresses key issues in clinical development and recently, six members companies have decided to extend the concept to the preclinical realm by establishing the subsidiary, BioCelerate.